AR117229A1 - Compuestos heteroaromáticos como inhibidores de vanina - Google Patents
Compuestos heteroaromáticos como inhibidores de vaninaInfo
- Publication number
- AR117229A1 AR117229A1 ARP190103518A ARP190103518A AR117229A1 AR 117229 A1 AR117229 A1 AR 117229A1 AR P190103518 A ARP190103518 A AR P190103518A AR P190103518 A ARP190103518 A AR P190103518A AR 117229 A1 AR117229 A1 AR 117229A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- membered
- optionally substituted
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
Abstract
Los compuestos de la fórmula (1), que son adecuados para el tratamiento de enfermedades relacionadas con vanina, y los procesos para fabricar estos compuestos, las preparaciones farmacéuticas que contienen estos compuestos y sus métodos de uso. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), o una sal de este aceptable desde el punto de vista farmacéutico, en donde n indica 1 ó 2; R¹, R² y R³ se seleccionan, independientemente entre sí, del grupo que consiste en C₁₋₄-alquilo opcionalmente sustituido con hidroxi, CH₃-O-, CH₃-SO₂-, fenil-CH₂- opcionalmente sustituido con 1 a 3 átomos de halógeno y heteroaril-C₁₋₂- alquil- de 5 - 6 miembros, o R² y R³ juntos forman un carbociclo de 3 - 6 miembros o un heterociclilo de 4 - 6 miembros que contiene un heteroátomo seleccionado del grupo que consiste en N y O; o R¹, R² y R³ juntos pueden formar un carbociclo bicíclico de 5 - 8 miembros o un heterociclilo bicíclico de 6 - 8 miembros que contiene un heteroátomo seleccionado del grupo que consiste en N y O; en donde, en la definición de R¹, R² y R³ mencionada, alquilo, cicloalquilo, heteroarilo y heterociclilo se sustituyen opcionalmente con 1 a 3 átomos de halógeno; R⁴ indica R⁴.¹R⁴.²N-, heteroarilo de 5 - 6 miembros, NC- o heterociclilo de 5 - 6 miembros; o R⁴ indica un grupo de la fórmula R⁴.ᵃ o R⁴.ᵇ en donde X indica CH₂, -NRX u O; en donde RX indica H o C₁₋₃-alquilo; R⁴.ᵃ y R⁴.ᵇ, independientemente entre sí, se sustituyen opcionalmente con metilo; R⁴.¹ se selecciona del grupo que consiste en C₁₋₄-alquil-CO- opcionalmente sustituido con 1 - 3 átomos de F, C₃₋₄-cicloalquilo o C₁₋₂-alcoxi, C₃₋₅-cicloalquil-CO- sustituido con R⁴.¹.¹ y R⁴.¹.², heterociclil-CO- de 4 - 6 miembros sustituido con R⁴.¹.³ y R⁴.¹.⁴, heterociclil-CH₂-CO- de 4 - 6 miembros, heteroaril-CO- de 5 - 6 miembros opcionalmente sustituido con 1 átomo de halógeno, H₃C-O- o 1 a 2 metilo, fenil-CO- sustituido con R⁴.¹.⁵ y R⁴.¹.⁶, (C₁₋₃-alquil)(C₁₋₃alquil)N-CO- y heteroarilo de 5 - 6 miembros; en donde R⁴.¹.¹, R⁴.¹.² se seleccionan, independientemente entre sí, del grupo que consiste en H, -CH₃, F, CF₃ y -CN; R⁴.¹.³, R⁴.¹.⁴ se seleccionan, independientemente entre sí, del grupo que consiste en H, -CH₃, F, CF₃ y -CN; R⁴.¹.⁵, R⁴.¹.⁶ se seleccionan, independientemente entre sí, del grupo que consiste en H, -CH₃, F, CF₃ y -CN; R⁴.² se selecciona del grupo que consiste en H, C₁₋₄-alquilo, C₃₋₄-cicloalquilo, C₃₋₄-cicloalquil-C₁₋₂-alquil- y fenil-C₁₋₂-alquil-; en donde, en la definición de R⁴.² mencionada, alquilo, cicloalquilo y fenilo se sustituyen opcionalmente con 1 - 3 átomos de F o un C₁₋₂-alquil-O; R⁵ indica H o C₁₋₂-alquilo; o R⁴ y R⁵ juntos forman un heterociclilo de 4 - 6 miembros que contiene 1 heteroátomo seleccionado del grupo que consiste en N y O; o una sal de aquel aceptable desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18209721 | 2018-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117229A1 true AR117229A1 (es) | 2021-07-21 |
Family
ID=64572152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103518A AR117229A1 (es) | 2018-12-03 | 2019-12-02 | Compuestos heteroaromáticos como inhibidores de vanina |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11078182B2 (es) |
| EP (1) | EP3891139A1 (es) |
| JP (2) | JP7130873B2 (es) |
| KR (1) | KR20210100150A (es) |
| CN (2) | CN114478485B (es) |
| AR (1) | AR117229A1 (es) |
| AU (1) | AU2019391279A1 (es) |
| BR (1) | BR112021007915A2 (es) |
| CA (1) | CA3116830A1 (es) |
| CL (2) | CL2021001198A1 (es) |
| CO (1) | CO2021007173A2 (es) |
| CR (1) | CR20210294A (es) |
| DO (1) | DOP2021000071A (es) |
| EA (1) | EA202191476A1 (es) |
| EC (1) | ECSP21040278A (es) |
| IL (1) | IL283397A (es) |
| JO (2) | JOP20210128A1 (es) |
| MA (1) | MA54378A (es) |
| MX (1) | MX2021006520A (es) |
| PE (1) | PE20211769A1 (es) |
| PH (1) | PH12021551280A1 (es) |
| SG (1) | SG11202104437XA (es) |
| WO (1) | WO2020114943A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20210478A1 (es) | 2018-08-28 | 2021-03-11 | Boehringer Ingelheim Int | Compuestos heteroaromaticos como inhibidores de vanina |
| EP3890828A1 (en) * | 2018-12-03 | 2021-10-13 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds as vanin inhibitors |
| JP7130873B2 (ja) | 2018-12-03 | 2022-09-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | バニン阻害剤としてのヘテロ芳香族化合物 |
| US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| CN116768909A (zh) * | 2022-03-18 | 2023-09-19 | 上海美悦生物科技发展有限公司 | Vanin酶抑制剂的盐型、晶型及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| WO2005035524A1 (en) | 2003-10-09 | 2005-04-21 | Abbott Laboratories | Pyrrolidinyl urea derivatives as angiogensis inhibitors |
| CN104703965A (zh) * | 2012-09-25 | 2015-06-10 | 默克专利股份有限公司 | α羟基酰胺 |
| EP3303303A1 (en) | 2015-05-29 | 2018-04-11 | Pfizer Inc | Novel heterocyclic compounds as inhibitors of vanin-1 enzyme |
| US10906888B2 (en) | 2016-07-14 | 2021-02-02 | Pfizer Inc. | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme |
| WO2018228934A1 (en) | 2017-06-12 | 2018-12-20 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as vanin inhibitors |
| PE20210478A1 (es) | 2018-08-28 | 2021-03-11 | Boehringer Ingelheim Int | Compuestos heteroaromaticos como inhibidores de vanina |
| PL3891142T3 (pl) * | 2018-12-03 | 2023-01-02 | Boehringer Ingelheim International Gmbh | Związki heteroaromatyczne jako inhibitory waniny |
| EP3890828A1 (en) * | 2018-12-03 | 2021-10-13 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds as vanin inhibitors |
| JP7130873B2 (ja) | 2018-12-03 | 2022-09-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | バニン阻害剤としてのヘテロ芳香族化合物 |
-
2019
- 2019-12-02 JP JP2021531556A patent/JP7130873B2/ja active Active
- 2019-12-02 CN CN202210061725.6A patent/CN114478485B/zh active Active
- 2019-12-02 WO PCT/EP2019/083252 patent/WO2020114943A1/en active Application Filing
- 2019-12-02 EA EA202191476A patent/EA202191476A1/ru unknown
- 2019-12-02 JO JOP/2021/0128A patent/JOP20210128A1/ar unknown
- 2019-12-02 KR KR1020217020910A patent/KR20210100150A/ko unknown
- 2019-12-02 PE PE2021000809A patent/PE20211769A1/es unknown
- 2019-12-02 MA MA054378A patent/MA54378A/fr unknown
- 2019-12-02 CR CR20210294A patent/CR20210294A/es unknown
- 2019-12-02 SG SG11202104437XA patent/SG11202104437XA/en unknown
- 2019-12-02 MX MX2021006520A patent/MX2021006520A/es unknown
- 2019-12-02 BR BR112021007915-7A patent/BR112021007915A2/pt unknown
- 2019-12-02 AU AU2019391279A patent/AU2019391279A1/en active Pending
- 2019-12-02 JO JOP/2021/0127A patent/JOP20210127A1/ar unknown
- 2019-12-02 CA CA3116830A patent/CA3116830A1/en active Pending
- 2019-12-02 EP EP19817182.9A patent/EP3891139A1/en active Pending
- 2019-12-02 US US16/699,799 patent/US11078182B2/en active Active
- 2019-12-02 CN CN201980078414.7A patent/CN113166104A/zh active Pending
- 2019-12-02 AR ARP190103518A patent/AR117229A1/es unknown
-
2021
- 2021-04-16 DO DO2021000071A patent/DOP2021000071A/es unknown
- 2021-05-06 CL CL2021001198A patent/CL2021001198A1/es unknown
- 2021-05-24 IL IL283397A patent/IL283397A/en unknown
- 2021-05-31 CO CONC2021/0007173A patent/CO2021007173A2/es unknown
- 2021-06-01 PH PH12021551280A patent/PH12021551280A1/en unknown
- 2021-06-03 EC ECSENADI202140278A patent/ECSP21040278A/es unknown
- 2021-06-25 US US17/358,111 patent/US20220048885A1/en not_active Abandoned
- 2021-12-30 CL CL2021003568A patent/CL2021003568A1/es unknown
-
2022
- 2022-08-24 JP JP2022133354A patent/JP2022188014A/ja active Pending
- 2022-11-02 US US18/051,953 patent/US20230295112A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA202191476A1 (ru) | 2021-10-26 |
| CL2021001198A1 (es) | 2021-12-24 |
| EP3891139A1 (en) | 2021-10-13 |
| SG11202104437XA (en) | 2021-05-28 |
| WO2020114943A1 (en) | 2020-06-11 |
| PH12021551280A1 (en) | 2021-12-06 |
| US20230295112A1 (en) | 2023-09-21 |
| BR112021007915A2 (pt) | 2021-07-27 |
| US20220048885A1 (en) | 2022-02-17 |
| MA54378A (fr) | 2022-03-09 |
| CA3116830A1 (en) | 2020-06-11 |
| KR20210100150A (ko) | 2021-08-13 |
| MX2021006520A (es) | 2021-07-07 |
| CN114478485B (zh) | 2024-04-05 |
| CN114478485A (zh) | 2022-05-13 |
| US20200172508A1 (en) | 2020-06-04 |
| CN113166104A (zh) | 2021-07-23 |
| JP7130873B2 (ja) | 2022-09-05 |
| CL2021003568A1 (es) | 2022-11-04 |
| DOP2021000071A (es) | 2021-05-31 |
| JOP20210128A1 (ar) | 2023-01-30 |
| PE20211769A1 (es) | 2021-09-07 |
| TW202039461A (zh) | 2020-11-01 |
| JOP20210127A1 (ar) | 2023-01-30 |
| IL283397A (en) | 2021-07-29 |
| JP2022509317A (ja) | 2022-01-20 |
| ECSP21040278A (es) | 2021-07-30 |
| CO2021007173A2 (es) | 2021-06-21 |
| JP2022188014A (ja) | 2022-12-20 |
| CR20210294A (es) | 2021-08-13 |
| US11078182B2 (en) | 2021-08-03 |
| AU2019391279A1 (en) | 2021-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117229A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| AR114164A1 (es) | Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| AR121016A2 (es) | Sales de fenotiazindiaminio y su uso | |
| AR112086A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR112834A1 (es) | Derivados de rapamicina | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR102722A2 (es) | Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit | |
| AR107488A1 (es) | Compuestos de benzopirazol y análogos de éstos | |
| AR123672A2 (es) | Conjugados de anticuerpo fármaco | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR116022A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR113299A1 (es) | Compuestos de isoindolina | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR117544A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
| AR054277A1 (es) | Derivados de piperidin - 4 - il - amida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con la modulacion de receptores del subtipo 5 de la sst. | |
| AR084731A1 (es) | Derivados de imidazoquinolina sustituidos | |
| AR108864A1 (es) | Agentes antibacterianos | |
| AR096041A1 (es) | Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg | |
| AR123757A1 (es) | Inhibidores de las cinasas raf | |
| AR090323A1 (es) | Imidazopiridazinas sustituidas, procesos e intermediarios para su obtencion y su uso en el tratamiento de enfermedades mediadas por la quinasa mps-1 |